AlphaStocks
6.3
Consider Buy

Ligand Pharmaceuticals Inc (LGND)

As of Sep 20, 2026, Ligand Pharmaceuticals Inc (LGND) scores 6.3/10 on AlphaStocks' five-model composite, #35 of 168 Health Care stocks. At $284, LGND trades 112% above its model fair value of $134.

Health Care / Biotechnology

S&P SmallCap 600

$283.68

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 5 of 5 models — high confidence

Data as of Sep 20, 2026

#35out of 168 in Health Care

Is LIGAND PHARMACEUTICALS INC a Good Investment in 2026?

LIGAND PHARMACEUTICALS INC (LGND) scores 6.3 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates LIGAND PHARMACEUTICALS INC as Attractive (5/9). However, the Greenblatt Magic Formula model rates it Caution — Earnings yield 1.9% · ROC 16%. LIGAND PHARMACEUTICALS INC currently trades 112% above its estimated fair value of $134. LIGAND PHARMACEUTICALS INC ranks #35 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E46.3ROE12.7Market Cap6B

Estimated Fair Value

$133.57112% above

Trading above estimated fair value. P/e of 46x implies high growth expectations.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Attractive

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

PEG 3.3 · Fast Grower

Greenblatt

Caution

Earnings yield 1.9% · ROC 16%

Frequently Asked Questions

Is LIGAND PHARMACEUTICALS INC (LGND) a good investment?
As of Sep 20, 2026, Ligand Pharmaceuticals Inc (LGND) scores 6.3/10 on AlphaStocks' five-model composite, #35 of 168 Health Care stocks. At $284, LGND trades 112% above its model fair value of $134. That is a middle-of-the-pack score with no strong signal either way.
What is LIGAND PHARMACEUTICALS INC's Piotroski F-Score?
LIGAND PHARMACEUTICALS INC's Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is LGND overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $134, LGND appears overvalued. The stock currently trades 112% above its estimated fair value. Trading above estimated fair value. P/e of 46x implies high growth expectations.
How does LGND compare to other Health Care stocks?
LIGAND PHARMACEUTICALS INC ranks #35 out of 168 stocks in the Health Care sector, placing it in the top 21% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about LGND?
AlphaStocks evaluates LGND using five proven investment models. Piotroski: Attractive; Buffett: Attractive; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 6.3/10.

Similar Stocks

ABBVINCYHRMY

Compare LGND with

ABBV vs LGNDINCY vs LGNDHRMY vs LGND

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer